Upgrade to SI Premium - Free Trial

Form 8-K ALLSCRIPTS HEALTHCARE For: Jun 21

June 22, 2022 4:12 PM
8-K
false000112480400011248042022-06-212022-06-21

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 21, 2022

 

 

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-35547

36-4392754

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

222 Merchandise Mart

 

Chicago, Illinois

 

60654

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 800 334-8534

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.01 per share

 

MDRX

 

NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

At the 2022 Annual Meeting held on June 21, 2022, the stockholders of the Company voted on the following three proposals and cast their votes as described below:

1.
The individuals listed below were elected at the 2022 Annual Meeting to serve as directors of the Company until the next annual meeting of stockholders and until their successors are duly elected and qualified.

 

For

Against

Abstain

Broker Non-Vote

Elizabeth A. Altman

95,520,720

192,360

50,067

7,979,355

P. Gregory Garrison

81,004,632

14,705,263

53,252

7,979,355

Jonathan J. Judge

73,769,204

20,686,603

1,307,340

7,979,355

Richard J. Poulton

95,544,700

170,388

48,059

7,979,355

Dave B. Stevens

94,053,938

402,442

1,306,767

7,979,355

Carol J. Zierhoffer

95,522,530

191,053

49,564

7,979,355

 

2.
A management proposal to ratify the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022, as described in the proxy materials, was approved.

For

Against

Abstain

Broker Non-Vote

103,282,184

403,617

56,701

0

 

3.
A non-binding, advisory resolution to approve named executive officer compensation, as described in the proxy materials, was approved.

For

Against

Abstain

Broker Non-Vote

94,529,262

1,166,141

67,744

7,979,355

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

 

 

 

 

Date:

June 22, 2022

By:

/s/ Eric Jacobson

 

 

 

Eric Jacobson
Senior Vice President and Corporate Secretary

 


Categories

SEC Filings